Shopping Cart
Remove All
Your shopping cart is currently empty
ARF(26–44) acetate（935732-44-8 Free base）
Catalog No. TP2731L Copy Product Info
Purity: 99.75%
🥰Excellent
ARF(26–44) acetate is an antitumor peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. In studies treating mouse hepatocellular carcinoma (HCC), it acts as a functional inhibitor of FoxM1, demonstrating significant antitumor effects by effectively increasing tumor cell apoptosis and suppressing tumor cell proliferation and angiogenesis.
ARF(26–44) acetate（935732-44-8 Free base）
Copy Product Info🥰Excellent
Catalog No. TP2731L
ARF(26–44) acetate is an antitumor peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. In studies treating mouse hepatocellular carcinoma (HCC), it acts as a functional inhibitor of FoxM1, demonstrating significant antitumor effects by effectively increasing tumor cell apoptosis and suppressing tumor cell proliferation and angiogenesis.
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | - | In Stock | |
| 5 mg | $483 | - | In Stock | |
| 10 mg | $691 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.75%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ARF(26–44) acetate is an antitumor peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. In studies treating mouse hepatocellular carcinoma (HCC), it acts as a functional inhibitor of FoxM1, demonstrating significant antitumor effects by effectively increasing tumor cell apoptosis and suppressing tumor cell proliferation and angiogenesis. |
| Molecular Weight | 3645.34 |
| Formula | C151H271N69O35S |
| Smiles | N=C(N)NCCC[C@@H](N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CS)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CC(N)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O |
| Relative Density. | no data available |
| Sequence | {d-(Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg)}-Lys-Phe-Val-Arg-Ser-Arg-Arg-Pro-Arg-Thr-Ala-Ser-Cys-Ala-Leu-Ala-Phe-Val-Asn |
| Sequence Short | {d-(Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg)}-KFVRSRRPRTASCALAFVN |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | H2O: 33.3 mg/mL (9.13 mM)  | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ARF(26–44) acetate（935732-44-8 Free base） | purchase ARF(26–44) acetate（935732-44-8 Free base） | ARF(26–44) acetate（935732-44-8 Free base） cost | order ARF(26–44) acetate（935732-44-8 Free base） | ARF(26–44) acetate（935732-44-8 Free base） chemical structure | ARF(26–44) acetate（935732-44-8 Free base） formula | ARF(26–44) acetate（935732-44-8 Free base） molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.